NEW YORK (GenomeWeb News) – Epigenetics-based cancer test developer PrognosDx has named Joseph Vallner to be its new CEO. Vallner, who formerly was president and COO at Cell Genesys, will succeed founding President and CEO Kamran Tahamtanzadeh, who will continue to serve as chairman of the board of directors.

The company is preparing to launch its PrognoScore test to predict clinical outcomes and assess risk probabilities for prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.